ArticleAnnals of pancreatic cancer2020
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.
Article in Annals of pancreatic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancer.Journal of biological engineering · 2026Article
- Article
- A nanoparticle platform for the co-delivery of multiple antigen epitope peptides and STING agonist to lymph nodes for cancer immunotherapy.International journal of pharmaceutics · 2025Article
- PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer.Biomolecules · 2025Article
- Review
- Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments.Experimental hematology & oncology · 2025Article
- Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology.Experimental & molecular medicine · 2025Review
- EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment.Theranostics · 2025Article
- Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis.Journal of nanobiotechnology · 2024Article
- Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.Journal of hematology & oncology · 2024Article
- KPC-luciferase-expressing cells elicit an anti-tumor immune response in a mouse model of pancreatic cancer.Scientific reports · 2024Article
- Combating PDAC Drug Resistance: The Role of Ref-1 Inhibitors in Accelerating Progress in Pancreatic Cancer Research.Journal of cellular signaling · 2024Article
- CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.Gastroenterology · 2023Article
- Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.Journal of virology · 2023Article
- Senescence program and its reprogramming in pancreatic premalignancy.Cell death & disease · 2023Review
- A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy.Advanced healthcare materials · 2023Article
- Recent Developments in NSG and NRG Humanized Mouse Models for Their Use in Viral and Immune Research.Viruses · 2023Review
- The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.International journal of molecular sciences · 2022Article
- Immuno-oncology trends: preclinical models, biomarkers, and clinical development.Journal for immunotherapy of cancer · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is in urgent need of better diagnostic and therapeutic methods due to its late diagnosis, limited treatment options and poor prognosis. Finding the right animal models to recapitulate the tumor molecular pathogenesis and tumor microenvironment (TME) complexity is critical for preclinical immunotherapeutic and non-immunotherapeutic treatment developments. In this review, we summarize and evaluate popular preclinical animal models including patient-derived xenograft models, humanized mouse models, genetically engineered mouse models, and syngeneic mouse models. Through comparisons between these models in different research settings, we hope to provide guidance in finding the most relevant preclinical models to suit various research purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.